Cardiocomm Solut Stock Price, News & Analysis

CardioComm (OTC:EKGGF) terminated an October 1, 2025 royalty agreement and entered a $512,000 loan agreement dated November 3, 2025 with current lenders to fund completion, commercialization, launch and post‑launch support of its GEMS FLEX and 14‑day Holter/LTCM ECG software flagship product.

The loan bears 10% interest compounded monthly, is first‑secured by company assets, and includes issuance of 345,600 bonus common shares and 6,912,000 warrants exercisable at $0.05 until November 3, 2030. The transaction involves related parties and is subject to TSXV approval and MI 61‑101 exemptions.

CardioComm Solutions (TSXV: EKG) has secured a significant royalty-based financing arrangement valued at $1,036,958.49 with current debt lenders. The deal includes $432,000 in new capital and conversion of existing interest-bearing debt. The funding will support the commercialization of their flagship GEMS FLEX and 14-day Holter-Event LTCM ECG software platform.

The agreement involves three lenders: Xemxija Holdings, Etienne Grima (CEO), and ITF Ventures. Lenders will receive 33% royalty from company profits post-launch, with payments beginning September 2026. The deal includes issuance of 829,566 bonus shares and 16,591,335 warrants at $0.05 exercise price until October 2030.

CardioComm Solutions (TSXV: EKG) announced that CEO Etienne Grima has personally purchased an $80,000 loan from one of the company's third-party lenders. This loan was part of original loans totaling $600,000 first announced in December 2016.

The transaction represents a significant shift as all of CardioComm's debt is now held by company insiders. The loan terms remain unchanged, and the purchase was unanimously approved by the company's directors. This consolidation under insider control demonstrates management's confidence in CardioComm's strategic direction and enhances the company's ability to advance its commercialization plans without third-party debt dependencies.

CardioComm Solutions (TSXV: EKG), a provider of consumer heart monitoring and ECG software solutions, has completed its previously announced shares for debt transactions with four company directors. The company issued a total of 4,162,500 common shares at $0.01 per share to settle $41,625 in outstanding debt owed to directors for services provided in 2024 and early 2025.

The shares will be subject to a four-month hold period until December 1, 2025. The transactions qualify as "related party transactions" under MI 61-101 but are exempt from formal valuation and minority shareholder approval requirements as they fall below 25% of the company's market capitalization.

CardioComm Solutions (TSXV: EKG), a provider of consumer heart monitoring and ECG software solutions, has announced debt settlement agreements with its directors. The company will issue 4,162,500 common shares at $0.01 per share to settle $41,625 in outstanding debt for services rendered.

Additionally, the company granted 250,000 stock options to CEO Etienne Grima, exercisable at $0.05 per share for five years with immediate vesting. Both transactions are subject to TSX Venture Exchange approval and qualify as exempt related party transactions under MI 61-101.

CardioComm Solutions (TSXV: EKG, OTC: EKGGF), a medical ECG monitoring technology company, has announced alternative arrangements for accessing its Annual General Meeting (AGM) materials due to the ongoing Canada Post strike. The Meeting Materials for the December 11, 2024 AGM are available on SEDAR+ and the company's website.

Registered shareholders can contact the company directly at 1-877-977-9425 or via email for proxy assistance, with a voting deadline of 11:00 a.m. EST on December 9, 2024. Beneficial shareholders should contact their brokers for proxy requests. Paper copies of meeting materials can be requested until December 6, 2024.

CardioComm Solutions (TSXV: EKG) has partnered with Sony to integrate its ECG technology into Sony's mSafety platform. The integration enables users to connect CardioComm's HeartCheck CardiBeat ECG monitor to the mSafety watch via Bluetooth, recording 30-second ECGs without requiring a smartphone. The system allows real-time ECG viewing on the watch and secure sharing with healthcare professionals through CardioComm's SMART Monitoring service. Key applications include early heart anomaly detection, post-hospital monitoring, long-term arrhythmia tracking, pharmacy-based screenings, and pharmaceutical trials. CardioComm plans to expand bio-signal collection capabilities through additional connected digital health monitoring devices.

CardioComm Solutions (TSXV: EKG) has been awarded up to $150,000 in funding from the Canadian Space Agency (CSA) to design a prototype for the next generation Connected Care Medical Module (C2M2). The company's GEMS™ C2M2 will be an AI-supported system designed for medical care in isolated environments, both in space and on Earth.

Key components of GEMS™ C2M2 include:

• AI-supported computer system for integrating medical technologies
• Plug-and-play architecture for flexible configurations
• Autonomous healthcare management capabilities
• Detection, diagnosis, treatment, and monitoring functionalities

The prototype design is due on October 28, 2024. If selected, CardioComm could receive up to $650,000 for further development of the C2M2 solution.

CardioComm Solutions, Inc. (TSXV: EKG) has received Health Canada clearance for its GEMS™ Rhythm ECG artificial intelligence (AI) software for automated detection of multiple arrhythmias and morphology abnormalities. The software will detect conditions such as atrial fibrillation, prolonged QT intervals, tachycardia, bradycardia, and more. This clearance is a critical milestone in developing GEMS™ into an all-in-one, device-agnostic ECG software solution.

GEMS™ Rhythm will be initially offered with GEMS™ FLEX ECG software for analyzing ECG data from event recorders worn up to 30 days. Future releases will include integration with GEMS™ Holter and GEMS™ LTCM solutions for continuous monitoring over 24 hours to 14 days. The NRC Industrial Research Assistance Program provided partial funding support of up to $150,000 for this project.